Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of its drug for Lou Gehrig’s disease, acknowledging it didn't help patients with the deadly neurological condition. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
출처: AP - 🏆 728. / 51 더 많은 것을 읽으십시오 »
Controversial ALS Drug May Be Pulled from Market After Disappointing Trial ResultsFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.
출처: MedicineNet - 🏆 575. / 51 더 많은 것을 읽으십시오 »